【摘要】 目的评估高选择性β2受体激动剂硫酸沙丁胺醇在儿童支气管哮喘轻中度急性发作治疗中的临床疗效与安全性。方法门诊诊断为哮喘轻中度急性发作的5～13岁患儿104例,随机分为硫酸沙丁胺醇缓释胶囊组(A组,52例)和丙卡特罗组(B组,52例)。观察2周,记录患儿哮喘日间及夜间症状评分及清晨峰流速值占正常预计值的百分比(PEFam%),在治疗前及治疗第7、14天检查肺功能,记录1 s用力呼气量占正常预计值的百分比(FEV1%),评估临床疗效评分及有效率,记录不良反应。结果 A组在治疗后第7、14天的哮喘日间症状、夜间症状、FEV1%、PEFam%与治疗前比较,均有明显改善,差异有统计学意义(P均<0.001);与B组比较,差异均无统计学意义(P>0.05)。A组临床总有效率、不良反应事件发生率与B组相比差异均无统计学意义(χ2=3.041、0.343,P均>0.05)。结论硫酸沙丁胺醇缓释胶囊在治疗哮喘轻中度急性发作中能较好改善患儿的临床症状及肺功能,缓解喘息,维持症状稳定,有较好的安全性。[临床儿科杂志,2011,29(10):967-970]更多还原

【Abstract】 Objective To evaluate the clinical efficacy of salbutamol sulfate sustained-release capsules in treatment of patients with mild and moderate exacerbations of asthma.Methods This study was a 2-week,randomized,control open trial.A total of 104 children diagnosed as mild to moderate exacerbations of asthma were enrolled and divided into two groups.The subjects were administrated orally salbutamol sulfate sustained-release capsules(group A,52 subjects)or procaterol tablets(group B,52 subjects)for two weeks.Efficacy was assessed by recording daytime and nighttime symptom scores,lung function tested before treatment,at treatment of 7 and 14 days including peak respiratory flow in predicted normal in the morning(PFEam%),and forced expiratory volume at 1 second in predicted normal(FEV1%).The adverse events had also been recorded.Results The daytime and nighttime symptom scores,FEV1%,and PEFam% at treatment of 7 and 14 days were significantly improved than those before treatment in group A(all P < 0.05),which were similar with group B.The clinical efficacy and total adverse events were no difference between group A and group B(χ2 = 3.041,0.343,all P > 0.05).Conclusions Salbutamol sulfate sustained-release capsules can effectively relieve the symptom,improve lung function,rescue exacerbations,and maintain release of symptoms,which is safe and can be applied to release mild and moderate exacerbations of asthma in children.更多还原